[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multi-omics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multi-omics":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638551","multi-omics-inflammatory-phenotype-for-abpa-recurrence-risk-prediction-100638551",false,"NCT07611838","Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction","Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study","Inclusion Criteria:\n\n* Female and Male patients aged 18-80 years\n* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria\n\nExclusion Criteria:\n\n* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)\n* Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.\n* Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.\n* Pregnant or lactating women.\n* Patients with missing key data or incomplete medical records.","ALL","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.",[25,26,27,28,29],"Allergic Bronchopulmonary Aspergillosis (ABPA)","Machine Learning","Multi-omics","Multicenter Study","Relapse",[31,29,26,28,27],"Allergic Bronchopulmonary Aspergillosis","RECRUITING","2026-05-28",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2021-01-01",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Qianfoshan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100584802","dongzong-cardiovascular-bio-imaging-registry-study-100584802","NCT06894095","Dongzong Cardiovascular Bio-imaging Registry Study","DAILY","Inclusion Criteria:\n\n* Aged ≥18 years\n* Coronary CT angiography performed\n* Informed consent acquired\n\nExclusion Criteria:\n\n* Unable to complete the follow-up\n* Serious chronic kidney disease (eGFR\\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n* Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 3 times the upper limit of normal)\n* Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc.\n* Suspected or known infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV)\u002Facquired immunodeficiency syndrome (AIDS), and Treponema pallidum (syphilis), etc.",true,{"count":54,"type":21},50000,"The DAILY project is a large-scale, multicenter, prospective initiative designed to establish a comprehensive bio-imaging database that integrates multidimensional data, including living environments, psychosocial and cognitive assessments, advanced lung and cardiovascular imaging, multi-omics profiles, clinical medication and surgical records, and health outcomes. Leveraging this extensive, multiscale dataset, the project aims to elucidate the intricate interplay between genetic biology and environmental factors in driving downstream biological alterations, thereby shaping lung and cardiovascular structural and functional phenotypes, and ultimately influencing the onset and progression of cardiovascular diseases (CVD). Through a systematic exploration and understanding of this complex network, the project seeks to identify critical intervention points and develop innovative strategies for the prevention and management of CVD.",[57,27,58,59],"Cardiovascular Diseases","Living Environments","Pulmonary-cardiovascular Imaging","2025-03-19",{"date":62,"type":36},"2025-03-25",{"date":64,"type":36},"2023-05-24",{"date":66,"type":21},"2038-05-31",{"name":68,"class":43},"Jinling Hospital, China",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100550859","neurophenotype-predicts-cd-disease-progression-100550859","NCT06452550","Neurophenotype Predicts CD Disease Progression","Multimodal MRI-based Neurophenotype Reflecting Brain-gut Interactions to Predict Intestinal Disease Progression in Patients With Crohn's Disease","Inclusion Criteria:\n\n* (a) CD patients aged 18-45 years; (b) the completion of multimodal brain MRI and administration of psychological questionnaires; (c) MR enterography (MRE), ileocolonoscopy, and blood or faecal samples, collection within one week of brain MRI; (d) a follow-up of at least six months for patients without disease progression; and (e) right-handedness.\n\nExclusion Criteria:\n\n* (a) recent use of antibiotics, probiotics, or prebiotics within three months prior to inclusion; (b) history of neurosurgery, cerebrovascular disease, or brain trauma; (c) use of central nervous system drugs or antidepressants within three months prior to inclusion; (d) identification of brain lesions on MR scan; (e) claustrophobia; or (f) presence of metal implants.","45 Years",{"count":78,"type":21},500,"The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using multiomics data to interpret the model.\n\nParticipants will be followed-up of at least six months for patients without disease progression to assess the relationship between neurophenotype and intestinal outcomes.",[81,27],"Radiomics",[83,84,85,86],"Abdominal MRI","Magnetic Resonance Imaging","Crohn's disease","Brain\u002Fgut interaction","2024-06-05",{"date":89,"type":36},"2024-06-11",{"date":91,"type":36},"2021-05-01",{"date":93,"type":21},"2025-06-01",{"name":95,"class":43},"First Affiliated Hospital, Sun Yat-Sen University"]